TK2D Treatment Safety: Dose Reduction, Diarrhea, and Elevated Transaminases

"TK2D Treatment Safety: Dose Reduction, Diarrhea, and Elevated Transaminases" takes up the question of what the safety data mean for monitoring in practice.

Dr. Hirano asks what clinical trials showed about discontinuing therapy and how that shapes safety monitoring. Dr. Zolkipli-Cunningham calls the data reassuring. In the pooled safety population, treatment-emergent adverse events were manageable and did not require permanent discontinuation. Among 67 treated patients, 16, or 23%, had an event that led to dose reduction, while only 9, or 13%, discontinued because of a perceived adverse event. Dose reduction is an effective strategy, since stepping down one dose tier often lets symptoms such as diarrhea attenuate.

Diarrhea was the most frequent adverse event and was generally mild or moderate. It commonly resolved after dose reduction, and only 2 of 67 patients, or 3%, discontinued because of it. She adds that vomiting and abdominal pain should be assessed too, but complex mitochondrial patients make it hard to attribute symptoms to the medicine alone, so a full clinical evaluation is key.

She also notes that ALT and AST elevations were seen in treated patients. Interpretation must account for the fact that patients with TK2D may already have elevated transaminases, as is true in other mitochondrial disease. Dr. Hirano points out that transaminases can rise from muscle, liver, or both, and asks how to work this up.

Dr. Zolkipli-Cunningham says any patient with myopathy can have an elevated CK, and measuring CK and related muscle markers helps clarify the source. She notes that ALT can rise when CK is elevated. When evaluating the liver, she includes gamma GT, bilirubin, and the full liver panel. Dr. Hirano reassures viewers that dose reduction or a temporary pause can resolve complications, so clinicians should not give up on the therapy.

Our next episode, "TK2D Treatment Access and Setting Realistic Expectations for Families," turns to insurance review, specialty pharmacy, and how to counsel the parents of a child whose treatment begins years into the disease.